January 30, 2025 03:52 PM EST
Pharma
FDA+

FDA ap­proves Ax­some's acute mi­graine treat­ment af­ter 2022 re­jec­tion

Max Gelman

Senior Editor

More than two and a half years af­ter the FDA re­ject­ed its mi­graine treat­ment, Ax­some Ther­a­peu­tics re­ceived an ap­proval for the drug on Thurs­day to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

Black­stone se­cures $1.6B so far for new life sci­ences fund tar­get­ed at $5B+

Take­da scraps pro­grams as it rais­es full-year guid­ance 

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Sanofi is in the mar­ket for M&A, thanks to ‘strong’ bal­ance sheet

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times